Radiosensitizers: a conference preview.
D000818:Animals; D001388:Aziridines / Q000627:therapeutic use; D019328:Buthionine Sulfoximine; D002330:Carmustine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004357:Drug Synergism; D017341:Etanidazole; D006801:Humans; D007659:Ketones / Q000627:therapeutic use; D008130:Lomustine / Q000627:therapeutic use; D008298:Maleates / Q000627:therapeutic use; D008717:Methionine Sulfoximine / Q000031:analogs & derivatives / Q000627:therapeutic use; D051379:Mice; D008920:Misonidazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D009593:Nitroimidazoles / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*
D001388:Aziridines; D007659:Ketones; D008298:Maleates; D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; D008717:Methionine Sulfoximine; D017341:Etanidazole; D019328:Buthionine Sulfoximine; C100099:tretazicar; D008130:Lomustine; C041712:1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol; C018637:phorone; D008920:Misonidazole; C014476:diethyl maleate; C009997:desmethylmisonidazole; D002330:Carmustine